Related Experiment Videos
Extended type 1 chain glycosphingolipids: dimeric Lea (III4V4Fuc2Lc6) as human tumor-associated antigen
M R Stroud1, S B Levery, E D Nudelman
1Biomembrane Institute, Seattle, Washington.
The Journal of Biological Chemistry
|May 5, 1991
Summary
Researchers identified a novel tumor-associated glycolipid antigen, dimeric Lea, in human cancer tissues. This finding advances understanding of cancer biomarkers and potential diagnostic targets.
Area of Science:
- Glycobiology
- Cancer Research
- Immunochemistry
Background:
- Human cancer tissues and cell lines contain a unique slow-migrating glycolipid.
- This glycolipid reacts strongly with monoclonal antibody (mAb) NCC-ST-421, raised against gastric adenocarcinoma.
- It shows weak cross-reactivity with anti-Lea monoclonal antibodies.
Purpose of the Study:
- To isolate and elucidate the structure of the slow-migrating glycolipid found in cancer tissues.
- To characterize the reactivity of mAb NCC-ST-421 with various glycolipid structures.
- To identify novel tumor-associated carbohydrate antigens.
Main Methods:
- Isolation of glycolipid from Colo205 cell line using chromatography.
- Structural elucidation via enzymatic degradation, mass spectrometry, and NMR spectroscopy.
- Immunostaining with various monoclonal antibodies to assess antigenicity.
Main Results:
- The major slow-migrating glycolipid was identified as dimeric Lea.
- mAb ST-421 demonstrated equal reactivity with dimeric Lea and Lea/Lex hybrid antigens.
- Reactivity was lower with simple Lea and extended Lea structures, and absent with dimeric Lex.
Conclusions:
- The primary tumor-associated glycolipid recognized by mAb ST-421 possesses a dimeric Lea structure.
- This structure represents a novel tumor-associated epitope due to extended type 1 chain elongation.
- This discovery offers potential for new cancer biomarker development.